Received 100% Good Feedback Peptide Glow Blend Injection Peptides Glow 70mg

Function

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. This drug is an investigational therapy that reduced body weight in a phase 2 trial when administered as monotherapy in participants without diabetes and with a BMI of at least 30 kg/m2 or at least 27 kg/m2 with hypertension or dyslipidaemia

1. Immunomodulation: Cagrilintide can enhance the activity of immune cells, promote the activity of macrophages and lymphocytes, and enhance the body's immunity, which is of great significance for improving the body's immunity and preventing and treating infectious diseases.
2. Antioxidation: Cagrilintide can remove free radicals in the body, reduce the harm of oxidation, protect the integrity and health of cells, and protect the health of cells and organs.
3. Promote growth and development: Cagrilintide can stimulate the growth and differentiation of cells, promote growth and development, promote weight gain, and enhance physical fitness.
4. Lowering blood sugar: Cagrilintide can lower blood sugar, prevent and treat diabetes.
5. Lipid-lowering: Cagrilintide can reduce the content of cholesterol and triacylglycerol in the blood, prevent and treat diseases such as hyperlipidemia.
6.In addition to the above effects, Cagrilintide also has the effect of protecting the liver.
Principle of action
Cagrilintide, a non-selective agonist, is designed for weekly subcutaneous injection at low pH. It is based on the h-amylin backbone, drawing inspiration from calcitonin, and exhibits a prolonged action profile, likely attributed to reversible albumin binding similar to semaglutide. This amylin analog is currently under development in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in individuals with overweight and obesity. Amylin, co-secreted with from pancreatic beta cells, exerts its satiating effect through both the homoeostatic and hedonic brain regions. On the other hand, semaglutide, a GLP-1 receptor agonist, reduces appetite by acting on GLP-1 receptors in the hypothalamus, increases production, and decreases glucagon secretion, thus delaying gastric emptying. These distinct yet interconnected mechanisms of action of an amylin analog and a GLP-1 receptor agonist appear to synergistically reduce appetite

FAQ